Immunocore (IMCR) News Today $29.92 +0.05 (+0.17%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$29.90 -0.03 (-0.08%) As of 02/21/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025February 19 at 7:00 AM | globenewswire.comImmunocore (IMCR) Projected to Post Quarterly Earnings on WednesdayImmunocore (NASDAQ:IMCR) will be releasing earnings before the market opens on Wednesday, February 26.February 19 at 3:23 AM | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Short Interest UpdateImmunocore Holdings plc (NASDAQ:IMCR - Get Free Report) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 7,340,000 shares, a growth of 9.4% from the January 15th total of 6,710,000 shares. Based on an average trading volume of 264,000 shares, the days-to-cover ratio is currently 27.8 days. Currently, 15.1% of the company's shares are sold short.February 17, 2025 | marketbeat.comMorgan Stanley Remains a Hold on Immunocore Holdings (IMCR)February 6, 2025 | markets.businessinsider.comImmunocore Holdings plc (NASDAQ:IMCR) Receives Average Recommendation of "Moderate Buy" from BrokeragesImmunocore Holdings plc (NASDAQ:IMCR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating aJanuary 30, 2025 | marketbeat.comHC Wainwright Estimates Immunocore FY2029 EarningsImmunocore Holdings plc (NASDAQ:IMCR - Free Report) - Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Immunocore in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio forecasts that the company will postJanuary 28, 2025 | marketbeat.comImmunocore Holdings: Buy Rating Backed by Promising Pipeline and Strategic AdvancementsJanuary 27, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Immunocore (NASDAQ:IMCR)HC Wainwright reissued a "buy" rating and issued a $100.00 price target on shares of Immunocore in a report on Monday.January 27, 2025 | marketbeat.comCrossmark Global Holdings Inc. Increases Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)Crossmark Global Holdings Inc. increased its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 36.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,020 shares of the company's stock after purchasinJanuary 25, 2025 | marketbeat.comBuy Rating Affirmed for Immunocore Holdings Amid Strategic Advancements and Promising Pipeline DevelopmentsJanuary 24, 2025 | markets.businessinsider.comImmunocore (NASDAQ:IMCR) Trading Up 6.1% - Should You Buy?Immunocore (NASDAQ:IMCR) Stock Price Up 6.1% - Here's WhyJanuary 23, 2025 | marketbeat.comAnalysts Issue Forecasts for Immunocore FY2025 EarningsImmunocore Holdings plc (NASDAQ:IMCR - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Immunocore in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company wilJanuary 22, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Raises Holdings in Immunocore Holdings plc (NASDAQ:IMCR)Hennion & Walsh Asset Management Inc. boosted its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 125.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 49,608 shares of the company's stocJanuary 19, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Sees Large Volume Increase - Here's What HappenedImmunocore (NASDAQ:IMCR) Sees Large Volume Increase - Time to Buy?January 15, 2025 | marketbeat.comImmunocore Holdings: Promising Pipeline and Strategic Advancements Position for Positive OutlookJanuary 13, 2025 | markets.businessinsider.comBarclays Issues a Buy Rating on Immunocore Holdings (IMCR)January 13, 2025 | markets.businessinsider.comImmunocore announces 2025 strategic priorities at JPM ConferenceJanuary 10, 2025 | markets.businessinsider.comImmunocore Holdings Positioned for Growth with Strategic 2025 Priorities and Strong Financial OutlookJanuary 10, 2025 | markets.businessinsider.comImmunocore's (IMCR) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $71.00 target price on shares of Immunocore in a research note on Friday.January 10, 2025 | marketbeat.comImmunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 10, 2025 | globenewswire.comImmunocore to present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comImmunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesImmunocore Holdings plc (NASDAQ:IMCR - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen brokerages that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have asJanuary 5, 2025 | marketbeat.comImmunocore appoints Travis Coy as CFO and Head of Corporate DevelopmentJanuary 2, 2025 | markets.businessinsider.comImmunocore Names Non-Executive Board Member as CFOJanuary 2, 2025 | marketwatch.comImmunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate DevelopmentJanuary 2, 2025 | globenewswire.comState Street Corp Has $2.39 Million Position in Immunocore Holdings plc (NASDAQ:IMCR)State Street Corp grew its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 63.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 76,671 shares of the company's stock after purchasing an additional 29,897 shares durinJanuary 1, 2025 | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Shares Purchased by Principal Financial Group Inc.Principal Financial Group Inc. raised its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 25.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 546,318 shares of thDecember 28, 2024 | marketbeat.comImmunocore announces first patient dosed in Phase 1 trial of IMC-P115CDecember 23, 2024 | markets.businessinsider.comImmunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAMEDecember 23, 2024 | globenewswire.comImmunocore (NASDAQ:IMCR) Hits New 1-Year Low - Time to Sell?Immunocore (NASDAQ:IMCR) Hits New 52-Week Low - Time to Sell?December 19, 2024 | marketbeat.comImmunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancersDecember 17, 2024 | markets.businessinsider.comImmunocore Holdings plc (NASDAQ:IMCR) Sees Significant Decline in Short InterestImmunocore Holdings plc (NASDAQ:IMCR - Get Free Report) was the recipient of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 7,190,000 shares, a decrease of 5.4% from the November 15th total of 7,600,000 shares. Currently, 14.8% of the shares of the company are sold short. Based on an average daily trading volume, of 277,800 shares, the short-interest ratio is currently 25.9 days.December 17, 2024 | marketbeat.comImmunocore Hldgs (NASDAQ:IMCR) Stock, Short Interest ReportDecember 14, 2024 | benzinga.comMorgan Stanley Downgrades Immunocore Holdings plc - Depositary Receipt () (IMCR)December 14, 2024 | msn.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 91,033 Shares of Immunocore Holdings plc (NASDAQ:IMCR)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 7,437.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC).December 14, 2024 | marketbeat.comImmunocore (NASDAQ:IMCR) Sets New 12-Month Low - What's Next?Immunocore (NASDAQ:IMCR) Hits New 1-Year Low - Time to Sell?December 13, 2024 | marketbeat.comImmunocore's (IMCR) "Equal Weight" Rating Reiterated at Morgan StanleyMorgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 target price (down previously from $74.00) on shares of Immunocore in a report on Friday.December 13, 2024 | marketbeat.comImmunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trialDecember 11, 2024 | markets.businessinsider.comEORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanomaDecember 11, 2024 | finance.yahoo.comImmunocore Holdings plc (NASDAQ:IMCR) Receives Average Rating of "Moderate Buy" from AnalystsShares of Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued aDecember 11, 2024 | marketbeat.comImmunocore Is Adequately Valued, But Its Prospects Are UncertainDecember 10, 2024 | seekingalpha.comVerition Fund Management LLC Acquires New Position in Immunocore Holdings plc (NASDAQ:IMCR)Verition Fund Management LLC bought a new position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 23,755 shares of the company's stock, valued at approximately $739,000December 10, 2024 | marketbeat.comWellington Management Group LLP Raises Position in Immunocore Holdings plc (NASDAQ:IMCR)Wellington Management Group LLP increased its holdings in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 10.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,048,833 shares of the company's stDecember 9, 2024 | marketbeat.comTwo Sigma Advisers LP Acquires 300,200 Shares of Immunocore Holdings plc (NASDAQ:IMCR)Two Sigma Advisers LP lifted its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 65.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 757,700 shares of the company's stock after buying an additioDecember 8, 2024 | marketbeat.comFmr LLC Purchases 23,436 Shares of Immunocore Holdings plc (NASDAQ:IMCR)Fmr LLC raised its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,836,040 shares of the company's stock after buying an additionalDecember 4, 2024 | marketbeat.comImmunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanomaDecember 3, 2024 | globenewswire.comImmunocore Holdings plc (NASDAQ:IMCR) Shares Acquired by Bellevue Group AGBellevue Group AG increased its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 4.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,205,464 shares of the company's stock after purchasing anDecember 1, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Buys 107,656 Shares of Immunocore Holdings plc (NASDAQ:IMCR)Massachusetts Financial Services Co. MA increased its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 27.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 498,221 shares of the company's stock after acquirNovember 26, 2024 | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Shares Bought by BNP PARIBAS ASSET MANAGEMENT Holding S.A.BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 7.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 427,152 shares of the company's stock after purchasing an additional 29,689November 24, 2024 | marketbeat.comPrimecap Management Co. CA Boosts Stake in Immunocore Holdings plc (NASDAQ:IMCR)Primecap Management Co. CA grew its position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 26.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,472,020 shares of the company's stock after acquirinNovember 22, 2024 | marketbeat.com Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address IMCR Media Mentions By Week IMCR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMCR News Sentiment▼0.990.60▲Average Medical News Sentiment IMCR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMCR Articles This Week▼34▲IMCR Articles Average Week Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TLX News Today ELAN News Today LNTH News Today NUVL News Today CYTK News Today VRNA News Today GRFS News Today TGTX News Today KRYS News Today SWTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMCR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
